Overview

A Hase II/III Clinical Study to Evaluate HLX22 in Combination With HLX87 as First-Line Treatment in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2030-12-30

Target enrollment:

Participant gender:

Summary

The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

pertuzumab